29 results
POS AM
ADIL
Adial Pharmaceuticals Inc
24 Jun 22
Prospectus update (post-effective amendment)
5:11pm
cost of our clinical trials;
failure to demonstrate effectiveness during clinical trials;
slower than expected rates of subject recruitment … of such product candidate for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability
POS AM
ADIL
Adial Pharmaceuticals Inc
24 Jun 22
Prospectus update (post-effective amendment)
5:02pm
than expected rates of subject recruitment or difficulty obtaining investigators;
subject drop-out or discontinuation;
inability to monitor subjects … also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Inadequate
POS AM
2wl35yfl
6 Apr 21
Prospectus update (post-effective amendment)
12:00am
POS AM
90g o2v7h1js
6 Apr 21
Prospectus update (post-effective amendment)
12:00am
8-K
EX-99.1
nnove86txdgks5z2 y9
11 Jun 20
Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD™ Pivotal Phase 3 Trial in Poland
11:58am
POS AM
dxdt7pr
22 Apr 20
Prospectus update (post-effective amendment)
5:05pm
POS AM
ubxia7iehzf2vb
22 Apr 20
Prospectus update (post-effective amendment)
5:04pm
424B3
au1y4
2 Apr 19
Prospectus supplement
6:19am
424B4
leer0xh s1x3whryx4
22 Feb 19
Prospectus supplement with pricing info
4:06pm
10-K
w936z
19 Feb 19
Annual report
9:30am